Effects of Celecoxib After Percutaneous Coronary Intervention

Seoul National University

Status and phase: Completed; Phase 4

Conditions: Coronary Arteriosclerosis

Treatments: Drug: Celecoxib

Study type: Interventional

Funder types: Other

Identifiers

NCT00292721

134-가-37

Details and patient eligibility

About

Several studies including ours have reported that celecoxib improves endothelium-dependent vasodilation and reduces inflammation and neointimal hyperplasia. Our hypothesis is that celecoxib may reduce the late luminal loss after coronary stent implantation (paclitaxel-eluting stent.

Enrollment: 260 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Coronary artery disease with at least 1 de novo lesion greater than 50% stenosis on coronary angiography

Exclusion criteria

• Acute ST elevation MI
• Left main disease
• Contraindications to aspirin, clopidogrel or celecoxib
• Severe congestive heart failure
• Expected survival < 2 years
• Hepatic dysfunction
• Currently taking NSAIDs or any COX-2 inhibitor
• Renal dysfunction
• Use of warfarin

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

260 participants in 2 patient groups

Control

No Intervention group

Celecoxib

Active Comparator group

Treatment:

Drug: Celecoxib